Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)

PHASE2CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

October 31, 2009

Conditions
Colorectal Cancer
Interventions
DRUG

AZD2171

oral tablet

DRUG

5-fluorouracil

intravenous infusion

DRUG

Leucovorin

intravenous infusion

DRUG

Oxaliplatin

intravenous infusion

DRUG

Bevacizumab

intravenous infusion

Trial Locations (43)

Unknown

Research Site, Innsbruck

Research Site, Vienna

Research Site, Wels

Research Site, Bonheiden

Ressearch Site, Brussels

Research Site, Edegem

Research Site, Ghent

Research Site, Leuven

Research Site, Winnipeg

Research Site, Moncton

Research Site, Greater Sudbury

Research Site, Kingston

Research Site, Ottawa

Research Site, Toronto

Research Site, Montreal

Research Site, Chomutov

Research Site, Nová Ves pod Pleší

Research Site, Pardubice

Research Site, Prague

Research Site, Montpellier

Research Site, Saint-Herblain

Research Site, Berlin

Research Site, Freiburg im Breisgau

Research Site, Halle

Research Site, Hanover

Research Site, Heidelberg

Research Site, München

Research Site, Stuttgart

Research Site, Genova

Research Site, La Torretta

Research Site, Milan

Research Site, Napoli

Research Site, Rozzano

Research Site, A Coruña

Research Site, Barcelona

Research Site, Madrid

Research Site, Valencia

Research Site, Zaragoza

Research Site, Glasgow

Research Site, Ipswich

Research Site, Maidstone

Research Site, Newcastle upon Tyne

Research Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00278889 - Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | Biotech Hunter | Biotech Hunter